|
Delayed
Bombay S.E.
12:38:37 2026-10-27 am EDT
|
5-day change | 1st Jan Change | ||
| 2,324.65 INR | +2.34% |
|
+4.43% | +25.98% |
| Sep. 25 | Caplin Point Laboratories Limited Approves Appointment of D Muralidharan as Whole Time Director | CI |
| Aug. 14 | Caplin Point Laboratories Limited, Q1 2027 Earnings Call, Aug 12, 2026 |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CAPLIN POINT LABORATORIES LIMITED | Generic Pharmaceuticals | +2.34% | +4.43% | +25.98% | +15.17% | +171.57% | 1.78B |  |  | |
Select your edition
All financial news and data tailored to specific country editions
